Somatostatin pp 355-368 | Cite as

The Effects of Somatostatin and Selected Analogs on Lipid Absorption in Animals

  • Eve E. Slater
  • Howard M. Katzen
  • Ruth F. Nutt
  • Richard Saperstein
  • Sanford L. Steelman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 188)


Based upon the clinical finding that a Merck somatostatin-14 (S-14) analog (1) induced steatorrhea in man, we sought to develop animal models to study the effects of S-14 and a series of synthetic analogs on absorption.

Rats were trained to eat a diet (preweighed) containing 15% fat. Following the feeding period, the remaining diet was removed and the amount consumed recorded. This food conditioning of the rats was continued until the rats consumed approximately 15 g of the diet per day. Feces were collected and weighed prior to feeding periods. On test days, S-14 or analogs were administered sc to rats immediately prior to feeding. For each compound tested, fat absorption decreased in dose-dependent fashion. For example, S-14 at 0.5 mg/kg did not increase % of dietary fat in feces (% DFF). At 1.0 mg/kg, S-14 increased % DFF from 7.9 to 10.2 (p <0.01, pretest day vs test day), and at 10 mg/kg S-14, % DFF increased from 9.1 to 12.8 (p <0.001).

For each analog, the subcutaneous dose required to decrease fat absorption in rats was several orders of magnitude higher than the intravenous dose required to inhibit insulin and glucagon. Moreover, the threshold for production of statistically significant increases in fecal fat differed among analogs when compared to their endocrine potencies. One analog administered in the model for 14 days was shown to produce consistent fat malabsorption throughout the entire test period; however, this lipid malabsorption was substantially more pronounced on the first three days of the treatment period. When the compound was not administered on day 15, the % DFF significantly decreased.

In an attempt to develop a system more suitable for rapid screening, pancreatic secretagogues such as secretin or cholecystokinin, were administered intravenously to anesthetized rats whose duodena had been cannulated and perfused to enable collection of pancreatic secretions. Total amylase, lipase, and protein were determined in single animals in response to a secretagogue, both before and after iv pretreatment by S-14 or an analog. Pancreatic enzyme secretion in response to sequential secretagogue-stimulation was found to be reproducible for up to three injections and behaved in a dose-dependent fashion. In general, secretagogue-induced increases in amylase, lipase, and total protein were comparable.

Pretreatment with the S-14 analogs substantially inhibited secretagogue-induced pancreatic exocrine secretion and was dose-dependent. Individual potencies correlated well with the ability to inhibit endocrine hormone release (glucagon, insulin, and growth hormone), although one compound with significantly less exocrine inhibitory effect was noted.

Our experience demonstrates that it is possible to produce S-14-induced fat malabsorption in rats, when fed a lipid rich diet. The animal models described herein show that S-14 and selected S-14 analogs have different potencies to induce fat malabsorption in rat and to inhibit exogenously stimulated pancreatic enzyme release. Nonetheless, the potential clinical significance of these separations is difficult to predict.


Short Bowel Syndrome Gastric Inhibitory Polypeptide Pancreatic Enzyme Secretion Food Conditioning Lipid Malabsorption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Veber DF, Saperstein R, Nutt RF, Freidinger RM, Brady SF, Curley P, Perlow DS, Paleveda WJ, Colton CD, Zacchei AG, Tocco DJ, Holt DR, Vandlen RL, Gerich JE, Hall L, Mandarino L, Cordes EH, Anderson PS, Hirschmann R 1984 A superactive cyclic hexapeptide analog of somatostatin. Life Sci 34: 1371.PubMedCrossRefGoogle Scholar
  2. 2.
    Nutt RF, Veber DF, Curley PE, Saperstein R, Hirschmann R 1983 Somatostatin analogs which define the role of the lysine-9 amino group. Int J Peptide Protein Res 21: 66.CrossRefGoogle Scholar
  3. 3.
    Stewart JM, Morris DH Peptide alcohols. 1981. U.S. Pat. 4,254,023, 3/3/1981.Google Scholar
  4. 4.
    Folch J, Lees M, Sloane-Stanley GH 1957 A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497.PubMedGoogle Scholar
  5. 5.
    Katzen HM, Vicario PP, Green BG 1984 Characteristics of secretory responses of the rat exocrine pancreas in vivo to various secretagogues. (submitted for publication).Google Scholar
  6. 6.
    Katzen HM, Vicario PP, Green BG 1984 Inhibition of secretagogue induced, and stimulation of basal, enzyme secretions from rat exocrine pancreas by somatostatin and a hexapeptide analog. (submitted for publication).Google Scholar
  7. 7.
    Gerich JE 1981 Somatostatin. In: Brownlee M (ed) Handbook of Diabetes Mellitus. Garland STPM Press, New York, 1: 297.Google Scholar
  8. 8.
    Wahren J, Felig P 1976 Influence of somatostatin in carbohydrate disposal and absorption in diabetes mellitus. Lancet 2: 1213.PubMedCrossRefGoogle Scholar
  9. 9.
    Schusdziarra V 1980 Somatostatin - a regulatory modulator connecting nutrient entry and metabolism. Horm Metab Res 12: 563.PubMedCrossRefGoogle Scholar
  10. 10.
    Schusdziarra V 1983 Somatostatin - physiological and pathophysiological aspects. Scand J Gastroenterol 18: 69.Google Scholar
  11. 11.
    Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubenstein A, Aldor AM, Unger RH 1979 Somatostatinoma syndrome - biochemical, morphologic and clinical features. N Engl J Med 301: 285.PubMedCrossRefGoogle Scholar
  12. 12.
    Pipeleers D, Somers G, Gepts W, De Nutte N, De Vroede M 1979 Plasma pancreatic hormone levels in a case of somatostatinoma - diagnostic and therapeutic implications. J Clin Endocrinol Metab 49: 572.PubMedCrossRefGoogle Scholar
  13. 13.
    Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kuhl C, Jensen SL, Lundqvist G, Rehfeld JF, Schwartz TW 1977 Pancreatic somatostatinoma - clinical features and physiological implications. Lancet 1: 666.PubMedCrossRefGoogle Scholar
  14. 14.
    Gerich JE 1981 Somatostatin. In: Brownlee M (ed) Handbook of Diabetes Mellitus. Garland STPM Press, New York, vol. 1: 302.Google Scholar
  15. 15.
    Dharmsathaphorn K, Gorelick FS, Sherwin RS, Cataland S, Dobbins JW 1982 Somatostatin decreases diarrhea in patients with the short bowel syndrome. J Clin Gastroenterol 4: 521.PubMedCrossRefGoogle Scholar
  16. 16.
    Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J 1980 Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Int Med 92: 68.PubMedGoogle Scholar
  17. 17.
    Gerich JE, Schultz TA, Lewis SB, Karam JH 1977 Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus. Diabetologia 13: 537.PubMedCrossRefGoogle Scholar
  18. 18.
    Raskin P, Unger RH 1978 Hyperglucagonemia and its suppression-importance in the metabolic control of diabetes. N Engl J Med 299: 433.PubMedCrossRefGoogle Scholar
  19. 19.
    Hengl G, Prager J, Miorz R, Pointner H, Deutsch E 1980 Further examinations of the influence of somatostatin on triglyceride absorption. Wien Med Wochenschr 130: 49.PubMedGoogle Scholar
  20. 20.
    Hengl G, Prager J, Pointner H 1979 The influence of somatostatin on the absorption of triglycerides in partially gastrectomized subjects. Acta Hepato-Gastroenterol 26: 392.Google Scholar
  21. 21.
    Sakurai H, Dobbs RE, Unger RH 1975 The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat. Diabetologia 11: 427.PubMedCrossRefGoogle Scholar
  22. 22.
    Schusdziarra V, Rivier J, Dobbs R, Brown M, Vale W, Unger R 1978 Somatostatin analogs as glucagon suppressants in diabetes. Horm Metab Res 10: 563.PubMedCrossRefGoogle Scholar
  23. 23.
    Daumerie C, Henquin JC 1982 Somatostatin and the intestinal transport of glucose and other nutrients in the anaesthetized rat. Gut 23: 140.PubMedCrossRefGoogle Scholar
  24. 24.
    Schusdziarra V, Harris V, Arimura A, Unger RH 1979 Evidence for a role of splanchnic somatostatin in the homeostasis of ingested nutrients. Endocrinology 104: 1705.PubMedCrossRefGoogle Scholar
  25. 25.
    Koerker DJ, Hansen BC 1981 Influence of somatostatin on gastric motility and meal absorption in rhesus monkeys, Macaca Mulatta. Metabolism 30: 335.Google Scholar
  26. 26.
    Ross SA, Shaffer EA 1981 Somatostatin suppresses glucose and fat absorption and gastric inhibitory polypeptide ( GIP) secretion from the canine duodenum. Clin Res 29: 311A.Google Scholar
  27. 27.
    Schusdziarra V, Zyznar E, Rouiller D, Boden G, Brown JC, Arimura A, Unger RH 1980 Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. Science 207: 530.PubMedCrossRefGoogle Scholar
  28. 28.
    Rizza RA, Gerich JE 1978 Somatostatin and diabetes. In: Podolsky S (ed) Med Clin N Amer, WB Saunders Company, Philadelphia, 62: 735.Google Scholar
  29. 29.
    Ligumsky M, Goto Y, Debas H, Yamada T 1983 Prostaglandins mediate inhibition of gastric acid secretion by somatostatin in rat. Science 219: 301.PubMedCrossRefGoogle Scholar
  30. 30.
    Johansson C, Kollberg B, Efendic S, Uvnas-Wallensten K 1981 Effects of graded doses of somatostatin on gall bladder emptying and pancreatic enzyme output after oral glucose in man. Digestion 22: 24.PubMedCrossRefGoogle Scholar
  31. 31.
    Johansson C, Wisen 0, Efendic S, Uvnas-Wallensten K 1981 Effects of graded doses of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 22: 126.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Eve E. Slater
    • 1
  • Howard M. Katzen
    • 1
  • Ruth F. Nutt
    • 1
  • Richard Saperstein
    • 1
  • Sanford L. Steelman
    • 1
  1. 1.Merck Institute for Therapeutic ResearchRahwayUSA

Personalised recommendations